Simcere

AbbVie
Biotech

JPM25: AbbVie pens $1B deal for Simcere’s ph. 1 T-cell engager

The Big Pharma is handing Simcere an undisclosed upfront payment with the promise of up to $1.05 billion in milestones for the trispecific antibody.
James Waldron Jan 13, 2025 10:28am
Massachusetts General Hospital

Editas backer Partners taps Lilly to help raise $171M fund

Nov 9, 2017 6:48am